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ABSTRACT
Introduction: Checkpoint inhibitors, including the CTLA-4 blocking antibody ipilimumab, have become the
new standard therapy for many metastatic cancers. Development of anti-drug antibodies (ADAs) after
treatment with other biopharmaceuticals has been thoroughly described, but the induction of ADAs after
treatment with checkpoint inhibitors has been inadequately investigated. In this retrospective study, we
relate ipilimumab serum levels and anti-ipilimumab antibody levels to clinical outcomes in patients with
metastatic melanoma (MM).
Method: Serum samples from 31 patients with MM were analyzed for serum levels of ipilimumab and
ADAs to ipilimumab at baseline, and before the 2nd and 4th infusion using an in-house bead-based assay.
The results were correlated with progression-free survival (PFS) and overall survival (OS).
Results: Low serum levels of ipilimumab before the 2nd infusion correlated signiﬁcantly with a shorter OS
(p D 0.01) and PFS (p D 0.02). Eight patients (26%) were ADA-positive at either timepoint. ADA positivity
correlated signiﬁcantly with a shorter OS (p D 0.03) with a hazard ratio (HR) of 3.0 (95% CI: 1.2-7.8). Four
of 8 ADA-positive patients (50%) discontinued therapy before the 4th infusion due to disease progression,
compared to three of 23 (13%) ADA-negative patients.
Conclusion: We conﬁrm that low serum levels of ipilimumab are associated with a shortened OS, and
we show for the ﬁrst time that ADAs to ipilimumab are associated with shorter OS in patients with MM.
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Introduction
Ipilimumab (Yervoy) is a human IgG1/kappa monoclonal
antibody that blocks the inhibitory receptor cytotoxic T-lym-
phocyte antigen 4 (CTLA-4) on T cells.1 It was the ﬁrst check-
point-inhibitor approved for the treatment of unresectable or
metastatic melanoma (MM),2 and is currently being tested in
several other cancer types. Ipilimumab acts primarily by block-
ing the inhibitory CTLA-4 signaling pathway in effector T cells
and regulatory T cells.3 The introduction of ipilimumab in MM
patients has improved median survival to more than 10 months
with a 2-year survival rate of around 25%.4,5
The clinical response to ipilimumab varies from no beneﬁt to
sustained response, and even long-lasting, complete remission
(CR).6,7 Serious autoimmune grade 3 or 4 adverse events occur in
about 15–25% of patients.4 Several immunologic and disease-
related biomarkers, including tumor mutational load, absolute
lymphocyte peripheral counts, and the number of tumor-inﬁltrat-
ing CD8C lymphocytes have been suggested to correlate with clin-
ical response.8–11 In dose-escalation trials, high serum levels of
ipilimumab correlate directly with prolonged survival, but also
with increased immune-related toxicity.12–14
Anti-drug antibodies (ADAs) may appear after administra-
tion of therapeutic monoclonal antibodies, and may neutralize
drug target binding or enhance drug clearance, resulting in sub-
optimal levels of active drug and loss of treatment efﬁcacy.15–20
In addition, ADA development may cause hypersensitivity
reactions such as anaphylaxis, infusion reactions, and immune-
complex mediated diseases.21,22
Little is currently known about the clinical consequences of
ADA development to ipilimumab or other biologic anti-neoplastic
drugs. According to the Food and Drug Administration (FDA) in
the USA, ADAs are detectable in»5% of patients treated with ipi-
limumab, but a similar proportion of positive samples can be
found in individuals receiving placebo.23 The FDA does not report
on neutralizing ADAs, or any clinical consequences of ADA posi-
tivity. The public assessment report (EPAR) from the European
Medicines Agency (EMA) reports that less than 2% of patients
develop ADAs to ipilimumab, without occurrence of neutralizing
antibodies.24 A recent study showed that 13% of patients with
malignant melanoma and lung cancer treated with the anti-pro-
grammed-death-1 (anti-PD-1) checkpoint inhibitor nivolumab
developed ADAs.25 The ADAs were primarily non-neutralizing
and caused only a minor increase in drug clearance. In a subgroup
analysis of survival in lung cancer patients, no statistically signiﬁ-
cant correlation was found, and the ADAs were deemed clinically
irrelevant.
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In the present study, we investigated the association between
circulating levels of ipilimumab and ADAs to ipilimumab and
progression-free survival (PFS) and overall survival (OS) in
patients with MM.
Materials and methods
Patient population
This was a retrospective study conducted on samples collected
from patients in an observational study in stage IV MM treated
with ipilimumab monotherapy at Herlev University Hospital
between October 2012 and May 2014, published elsewhere.8
The patients received induction therapy of up to 4 treatment
series (3 mg/kg) about 3 weeks apart. Blood samples from 31
patients were available for inclusion. PFS and OS data were
retrieved from the Danish Melanoma Web Database adminis-
tered by the Clinical Research Unit (KFE) at Odense University
Hospital.
Blood sampling
Blood samples were drawn in dry Vacutainer tubes (BD Bio-
sciences, Lyngby, Denmark) before the 1st (baseline) and 2nd
and 4th ipilimumab infusions. Blood samples were left to coagu-
late, and serum was then isolated by centrifugation at 1000 g for
10 min and frozen at ¡80C until analysis.
Baseline blood samples were drawn a median of 5 days
(range: day 0–35) before the 1st infusion. Subsequent blood
samples were drawn before the 2nd” infusion at day 20 (range:
day 16–24), and before the 4th” infusion at day 62 (range: day
59–68) relative to the 1st infusion. To minimize the inﬂuence of
physiological drug clearance, blood samples drawn less than
18 days or more than 24 days after the previous infusion were
excluded from the analysis of serum drug levels, but not from
the ADA analysis.
Measurement of ADAs and serum levels of ipilimumab
Serum levels of ADAs and ipilimumab were measured using in-
house bead-based assays.
For measurement of serum levels of ipilimumab, recombi-
nant human CTLA-4 (Sino Biological, Beijing, China) was
covalently coupled to xMAP-beads (Luminex Corporation,
Eindhoven, Netherlands) using the xMAP Antibody Coupling
Kit (Luminex Corporation) as described by the manufacturer.
The most concentrated assay standard was prepared by diluting
ipilimumab stock in neat serum from blood group AB-positive
healthy donors (Sigma-Aldrich, Copenhagen, Denmark) to a
concentration of 60 mg/ml. A standard curve was then prepared
by three-fold serial dilutions with additional serum. Both stan-
dard curve and samples were diluted 1:1000 in phosphate buff-
ered saline containing 0.05% Tween-20 (PBST) and incubated
with CTLA-4 coupled beads for 2 hours at room temperature.
After three PBST washes, samples were incubated for 1.5 hours
at room temperature with a biotinylated goat anti-human
kappa light-chain detection antibody (Bio-Rad, Copenhagen,
Denmark). Following three additional PBST washes, samples
were incubated with a streptavidin-R-phycoerythrin-conjugate
(SA-R-PE) (ProZyme, Hayward, CA), washed three times with
PBST, and measured on a Luminex 100IS instrument (Luminex
Corporation). Standard curves used for quantifying samples on
the same plate were subsequently constructed using a ﬁve-
parameter sigmoidal ﬁt algorithm in Bio-Plex Manager v6.0
(Bio-Rad, Copenhagen, Denmark).
For ADA measurement, ipilimumab was covalently coupled
to xMAP beads using the xMAP Antibody Coupling Kit
(Luminex Corporation), as described by the manufacturer.
Serum samples were diluted 1:40 in PBST and incubated with
the ipilimumab-coupled beads for 2 hours at room tempera-
ture. After three PBST washes, samples were incubated for
1.5 hours at room temperature with a biotinylated goat anti-
human lambda light-chain detection antibody (Bio-Rad). Fol-
lowing three further PBST washes, samples were incubated
with SA-R-PE, washed three times with PBST, and subse-
quently quantitated on a Luminex 100IS instrument (Luminex
Corporation). Samples with an increase in median ﬂuorescence
intensity (MFI) by 25% from the crude baseline value in combi-
nation with a MFI exceeding 130 (the 75th percentile for base-
line samples) were deﬁned as ADA-positive. A positive ADA
status was considered as an irreversible risk factor.
Statistics
The Wilcoxon matched-pairs signed-rank test was used with
pairwise comparisons to determine the signiﬁcance of the dif-
ference between different timepoints. The Mann-Whitney U
test was used to test the difference in serum drug levels between
ADA-positive and ADA-negative patients. Cox proportional
hazards regression was used to determine hazard ratios with
95% conﬁdence intervals (CIs) and the signiﬁcance of differen-
ces in OS and PFS in relation to ADA status or circulating drug
levels. Positive ADA status was treated as a time-dependent
covariate to take changes in ADA status over time into account.
Cox proportional hazards regression was also used to test the
log-transformed MFI values from the ADA measurements for
a statistically signiﬁcant inﬂuence on OS and PFS. P-values
<0.05 were considered statistically signiﬁcant. Statistical analy-
ses were performed using R (R Foundation for Statistical Com-
puting, Vienna, Austria) and GraphPad Prism v7 (GraphPad
Software, La Jolla, CA).
Results
Patient characteristics and survival
Characteristics of the 31 patients included are shown in Table 1.
All patients received at least one infusion of ipilimumab; 24
patients (77%) received all four ipilimumab infusions. Clinical
data on hypersensitivity, e.g. drug rash or anaphylaxis, were not
available.
The patients had a median OS of 605 days (range: 62–1365
days) and a median PFS of 133 days (range: 32–1224 days) (Fig. 1).
Circulating serum levels of ipilimumab
Blood samples drawn before the 2nd infusion from 24 patients
were eligible for analysis of circulating ipilimumab, as were
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samples drawn before the 4th infusion from 20 patients
(Table 2). As expected, ipilimumab levels increased progres-
sively during the treatment period (Fig. 2).
The level of ipilimumab in blood samples drawn a few days
before the 2nd infusion (n D 24) correlated positively with OS
(p D 0.01) and PFS (p D 0.02), with hazard ratios per decreas-
ing mg/mL of serum ipilimumab of 1.3 (95% CI: 1.1-1.5) and
1.2 (95% CI: 1.0-1.4) respectively (Table 2). No correlation with
OS or PFS was observed for ipilimumab levels in samples
drawn before the 4th infusion (n D 20).
Seven patients (23%) developed early progressive disease,
identiﬁed as discontinuation of ipilimumab before the 4th
infusion due to disease progression. Blood samples from ﬁve of
these patients drawn before the 2nd infusion were eligible for
analysis, and three of these contained remarkably low ipilimu-
mab levels (2.1 mg/ml, 3.3 mg/ml and 4.6 mg/ml). The two
remaining patients had normal serum ipilimumab levels before
the 2nd infusion but low levels before the 4th infusion (8.6 mg/
ml and 12.8 mg/ml).
Development of ADAs to ipilimumab
Serum levels of ADAs to ipilimumab were also measured at
baseline, and before the 2nd and 4th infusions (Fig. 3). Seven
patients were ADA-positive before the 2nd infusion of ipilimu-
mab, and one patient turned positive between the 2nd and 4th
infusions. Thus, eight patients (26%) were ADA-positive at any
timepoint during the study period (Table 1). One patient had a
positive sample at the 2nd infusion but a negative sample at the
4th infusion.
ADA-positive patients had a signiﬁcantly shortened OS
(p D 0.03) with a median of 235 days (range: 67–927 days)
compared to the 658 days (range: 62–1365 days) in ADA-neg-
ative patients (Fig. 4A). The corresponding medians for PFS
were 80 days (range: 34–476 days) and 191 days (range:
55–1224 days), but this difference was not statistically signiﬁ-
cant (p D 0.08) (Fig. 4B). Thus, ADA positivity was associated
with a hazard ratio of 3.0 (95% CI: 1.2-7.8) for the shorter OS
(Table 3).
To allow for prejudice in our deﬁnition of ADA positivity,
we also correlated the log-transformed ADA-derived MFI
Table 1. Demographics of ipilimumab-treated stage IV malignant melanoma
patients.
Demographics All ADA-positive ADA-negative
No. of patients (n) 31 8 23
Age
Median (range) 67 (40–77) 67 (49–72) 67 (40–77)
Sex
Female 16 3 13
Male 15 5 10
Disease stage at baseline
M1a 6 2 4
M1b 4 0 4
M1c 21 6 15
Cerebral metastasis 5 2 3
Previous treatment
IL-2 13 4 9
Temozolomide 8 2 6
None 10 2 8
No. of ipilimumab infusions
1 1 0 1
2 2 2 0
3 4 2 2
4 24 4 20
ADA: Anti-drug antibodies measured before 2nd and 4th infusion of ipilimumab.
Patients with at least one positive sample were regarded as ADA-positive.
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Figure 1. Overall survival and progression-free survival. Thirty-one patients with
metastatic melanoma were treated with 1–4 infusions of ipilimumab (3 mg/kg)
and followed up for up to 1365 days. Shown are (A) overall survival (OS) and (B)
progression-free survival (PFS).
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Figure 2. Serum levels of ipilimumab. Serum ipilimumab (s-ipilimumab) levels in
31 patients with metastatic melanoma were measured at baseline, and before the
2nd and 4th infusions of ipilimumab. Seven samples drawn before the 2nd infusion
were excluded from analysis due to high background noise (n D 3) or a too long
or short interval since the previous infusion (n D 4). Eleven samples drawn before
the 4th infusion were unavailable for analysis because they were missing (n D 6),
or excluded due to high background signal (n D 2) or a too long or short interval
since the previous infusion (n D 3).
Table 2. Correlation of serum ipilimumab levels with overall and progression-free survival.
OS PFS
n s-ipilimumab in mg/ml median (range) HR (95% CI) per mg/ml p HR (95% CI) per mg/ml p
Before 2nd infusion 24 11.0 (2.1-18.7) 1.3 (1.1-1.5) 0.01 1.2 (1.0-1.4) 0.02
Before 4th infusion 20 19.0 (4.6-28.3) 1.0 (0.9-1.1) 0.69 1.0 (1.0-1.1) 0.30
Serum drug levels of ipilimumab in patients with metastatic melanoma were measured before the 2nd and 4th infusion of ipilimumab. Hazard ratios per decreasing con-
centration (1 mg/ml) of ipilimumab are shown. Hazard ratios and p-values were calculated using Cox proportional hazards regression model. PFS: Progression-free sur-
vival; OS: Overall survival; HR: Hazard ratio.
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values directly to the survival data and found a similar statisti-
cally signiﬁcant correlation with OS (p D 0.03), but not with
PFS (data not shown).
Of the eight patients who were ADA-positive, four (50%)
discontinued therapy before the 4th infusion of ipilimumab due
to progressive disease compared to only 3 out of 23 patients
(13%) in the ADA-negative group (Table 1).
Inﬂuence of ADA development on serum levels
of ipilimumab
We observed no association between ADA positivity and low
serum levels of ipilimumab neither before the 2nd or the 4th
infusion (Fig. 5), nor did ADA positivity before the 2nd infu-
sion correlate with the serum level of ipilimumab before the
4th infusion (data not shown).
It is noteworthy that two ADA-positive patients had consid-
erably lower serum levels of ipilimumab than the group
median. One of these patients had a level of 3.3 mg/mL before
the 2nd infusion, as compared to the group median of 10 mg/
mL. This patient stopped treatment before the 4th infusion due
to progressive disease and died shortly after. The other patient
had levels of 11.5 before the 2nd and 12.8 mg/mL before 4th
infusion; whereby the latter was markedly lower than the group
median of >19 mg/mL. This patient also discontinued therapy
before the 4th infusion due to progressive disease and died one
month later.
Discussion
The ipilimumab dose and corresponding serum level have pre-
viously been shown to affect treatment outcome in MM,12–14
but an inﬂuence of ADAs has not been reported. Circulating
ADAs may neutralize drugs and enhance drug clearance,26 and
a clinical inﬂuence of ADAs has been demonstrated after treat-
ment with a number of therapeutic monoclonal antibodies,
including tumor necrosis factor-alpha blockers,18–20 natalizu-
mab,27 cetuximab21 and rituximab.28
In keeping with the ﬁndings of others,12,13 we found that
high serum levels of ipilimumab before the 2nd of four infusions
correlate statistically signiﬁcantly with longer OS and PFS. The
absence of statistical signiﬁcance before the 4th infusion may be
a consequence of discontinued treatment and missing samples
in some patients with low drug levels or greater heteroscedas-
ticity of drug levels after three infusions than after one.
We detected ADAs in 26% of our ipilimumab treated
patients. The FDA and EMA have previously reported fre-
quencies of 5% and <2% respectively.23,24 The higher pro-
portions in our study are presumably a result of the
different testing methods and deﬁnitions of ADA positivity.
Overall, a positive ADA status was associated with statisti-
cally signiﬁcantly shortened OS and a markedly increased
HR. These results were conﬁrmed by analysis of the MFI
values independent of our deﬁnition of ADA positivity. The
association was statistically signiﬁcant for OS but not for
PFS. Considering the short PFS intervals, however, statisti-
cally signiﬁcant results cannot be expected in such a small
study population as examined here. The rate of therapy dis-
continuation before the 4th infusion due to progressive dis-
ease was also notably higher in ADA-positive patients
(50%) than in ADA-negative patients (13%).
To our knowledge, no other studies have demonstrated an
inﬂuence of ADAs on survival after treatment with ipilimumab.
In a recent study on another checkpoint inhibitor, the anti-PD-
1 antibody nivolumab, Agrawal et al. showed development of
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Figure 3. Anti-drug antibodies (ADAs) to ipilimumab. The levels of antibodies to
ipilimumab in serum from 31 patients with metastatic melanoma were measured
using a Luminex bead-based assay. The median ﬂuorescence intensity (MFI) values,
representing the ADA levels, are plotted on a logarithmic axis. Samples were
drawn at baseline, and before the 2nd and 4th infusions of ipilimumab. Six samples
drawn before 4th infusion were missing. ‘
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Figure 4. Overall and progression-free survival by ADA status. (A) The overall sur-
vival (OS) and (B) progression-free survival (PFS) of eight ADA-positive and twenty-
three ADA-negative patients with metastatic melanoma are shown. P-values were
calculated using Cox proportional hazards regression analysis.
Table 3. Clinical outcomes stratiﬁed by occurrence of anti-drug antibodies.
OS PFS
Median (range) HR (95% CI) p Median (range) HR (95% CI) p
ADA-positive 235 (67-927) 3.0 (1.2-7.8) 0.03 80 (34-476) 2.1 (0.9-5.0) 0.08
ADA-negative 658 (62-1365) 191 (55-1224)
Hazard ratios and p-values were calculated using Cox proportional hazards regression model. PFS: Progression-free survival (days); OS: Overall survival (days); HR: Hazard
ratio; CI: Conﬁdence interval.
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ADAs in 13% of patients with MM and lung cancer25 but, in
contrast to our ﬁndings, they did not observe a correlation
between ADA development and survival. However, the anti-
PD-1 antibodies may show a different dose-response relation-
ships from ipilimumab, as recently demonstrated for
pembrolizumab.29
We were not able to demonstrate that ADA positivity was
associated with lower serum levels of ipilimumab, although two
ADA-positive patients with poor clinical responses had remark-
ably low serum ipilimumab levels. It is noteworthy that ADAs of
clinical signiﬁcance (as indicated by survival data) were measured
as early as 16–24 days after the 1st infusion of ipilimumab. At this
timepoint, ADAs presumably have low afﬁnity and are unlikely to
elicit considerable drug clearance or to neutralize the binding of
ipilimumab to CTLA-4 in our assay for drug measurement.
Therefore, relatively high serum levels of ipilimumab may be mea-
sured in the presence of early ADAs, and the very presence of
early ADAs may anticipate afﬁnity maturation and development
of high-afﬁnity antibodies that neutralize ipilimumab or promote
its clearance from the circulation.
During the follow-up period of this study, treatment with
the PD-1 blocking antibody pembrolizumab was introduced as
a therapy option for patients with MM. Thus, some patients
who developed disease progression during or after ipilimumab
therapy were eligible to receive this treatment, which may have
prolonged their survival, leading to a potential underestimation
of the effects of ADA formation.
Our study has some limitations. Due to the low number of
participants, the study can only be regarded as exploratory. The
retrospective design limited the possibility of investigating rele-
vant clinical outcomes, such as hypersensitivity. The deﬁnition
of ADA positivity, based on both absolute levels and an
increase from baseline, was not ideal. A validated cut-off level
based, for example, on a human anti-ipilimumab positive con-
trol antibody would have been desirable. We used an anti-
lambda light chain antibody as detecting antibody, which has
proved as effective as other methods in the detection of ADAs
and prediction of clinical outcomes.30,31 However, it does not
detect ADAs with kappa light chains, nor does it distinguish
between different antibody isotypes.
Despite its limitations, our study conﬁrms that low drug lev-
els correlate with a poorer clinical outcome of ipilimumab
treatment in MM, and introduce the novel ﬁnding that early
ADAs to ipilimumab have prognostic value. If this can be
conﬁrmed in larger prospective studies, early detection of
ADAs and recognition of low serum levels of ipilimumab may
help clinicians in making timely decisions regarding dosing or
switching to other treatments.
Conclusion
This study suggests that the presence of ADAs to ipilimumab is
associated with shortened OS. We also conﬁrmed a correlation
between low serum drug levels and shortened OS and PFS.
These results warrant prospective studies on the clinical conse-
quences of ADAs on checkpoint inhibitors.
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